Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $36.0 million.

  • Inhibrx Biosciences' Total Current Liabilities fell 1839.66% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year decrease of 1839.66%. This contributed to the annual value of $40.7 million for FY2024, which is 2767.08% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Total Current Liabilities stood at $36.0 million for Q3 2025, which was down 1839.66% from $38.9 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Total Current Liabilities ranged from a high of $56.3 million in Q4 2023 and a low of $36.0 million during Q3 2025
  • Moreover, its 3-year median value for Total Current Liabilities was $40.7 million (2024), whereas its average is $42.7 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 2767.08% in 2024, then fell by 28.94% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Total Current Liabilities (Quarter) stood at $56.3 million in 2023, then decreased by 27.67% to $40.7 million in 2024, then fell by 11.65% to $36.0 million in 2025.
  • Its last three reported values are $36.0 million in Q3 2025, $38.9 million for Q2 2025, and $43.6 million during Q1 2025.